Anna Maria Lanzillo

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Regorafenib is an orally administered multikinase inhibitor indicated for the treatment of heavily pretreated metastatic colorectal cancer patients with good performance status, albeit less than 50% treated patients achieve disease stabilisation or better at the first radiological evaluation. In addition to that a particularly broad spectrum of toxicities(More)
  • 1